Lyell Immunopharma (LYEL) Non Operating Income (2020 - 2026)

Lyell Immunopharma's Non Operating Income history runs 7 years deep, the most recent figure standing at $17.9 million for Q1 2026.

• In Q1 2026, Non Operating Income rose 246.37% year-over-year to $17.9 million; the TTM figure through Mar 2026 stood at $11.6 million (up 28.54% YoY), while the FY2025 annual figure was -$5.0 million, down 207.46% from the prior year.
• Non Operating Income came in at $17.9 million for Q1 2026 at Lyell Immunopharma, up from -$2.7 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $17.9 million in Q1 2026 to a low of -$4.9 million in Q3 2025.
• A 5-year average of $2.0 million and a median of $1.1 million in 2024 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income soared 11434.09% in 2022 and tumbled 11200.0% in 2025, its largest moves.
• Lyell Immunopharma's Non Operating Income stood at $5.0 million in 2022, then slumped by 110.15% to -$506000.0 in 2023, then tumbled by 266.6% to -$1.9 million in 2024, then sank by 44.2% to -$2.7 million in 2025, then surged by 769.68% to $17.9 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $17.9 million, -$2.7 million, and -$4.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison